Zorad Stefan, Dou Jing-tao, Benicky Julius, Hutanu Daniel, Tybitanclova Katarina, Zhou Jin, Saavedra Juan M
Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovakia.
Eur J Pharmacol. 2006 Dec 15;552(1-3):112-22. doi: 10.1016/j.ejphar.2006.08.062. Epub 2006 Sep 9.
To clarify the mechanism of the effects of angiotensin II AT(1) receptor antagonists on adipose tissue, we treated 8 week-old male Wistar Kyoto rats with the angiotensin II AT(1) receptor antagonist Candesartan cilexetil (10 mg/kg/day) for 18 weeks. Candesartan cilexetil reduced body weight gain, decreased fat tissue mass due to hypotrophy of epididymal and retroperitoneal adipose tissue and decreased adipocyte size without changing the number of adipocytes. Candesartan cilexetil decreased serum leptin levels and epididymal leptin mRNA, increased serum adiponectin levels and epididymal adiponectin mRNA, decreased epididymal tumor necrosis factor alpha (TNFalpha) mRNA, and increased fatty acid synthase mRNA. Considered free of peroxisome proliferator-activated receptor gamma (PPARgamma) agonist activity, Candesartan cilexetil increased epididymal expression of PPARgamma mRNA. The effects of Candesartan cilexetil on adipokine production and release may be attributable to PPARgamma activation and/or decrease in adipocyte cell size. In addition, Candesartan cilexetil treatment increased the expression of epididymal angiotensin II AT(2) receptor mRNA and protein and decreased the expression of renin receptor mRNA. These results suggest that Candesartan cilexetil influences lipid metabolism in adipose tissue by promoting adipose tissue rearrangement and modulating adipokine expression and release. These effects are probably consequences of local angiotensin II AT(1) receptor inhibition, angiotensin II AT(2) receptor stimulation, and perhaps additional angiotensin II-independent mechanisms. Our results indicate that the activity of local renin-angiotensin system plays an important role in adipose tissue metabolism. The decrease in the pro-inflammatory cytokine TNFalpha and the increase in the anti-inflammatory adipokine adiponectin indicate that Candesartan cilexetil may exert significant anti-inflammatory properties.
为阐明血管紧张素II AT(1)受体拮抗剂对脂肪组织的作用机制,我们用血管紧张素II AT(1)受体拮抗剂坎地沙坦酯(10毫克/千克/天)对8周龄雄性Wistar Kyoto大鼠进行了18周的治疗。坎地沙坦酯减少了体重增加,由于附睾和腹膜后脂肪组织萎缩而降低了脂肪组织质量,并减小了脂肪细胞大小,而脂肪细胞数量未改变。坎地沙坦酯降低了血清瘦素水平和附睾瘦素mRNA,增加了血清脂联素水平和附睾脂联素mRNA,降低了附睾肿瘤坏死因子α(TNFα)mRNA,并增加了脂肪酸合酶mRNA。在无过氧化物酶体增殖物激活受体γ(PPARγ)激动剂活性的情况下,坎地沙坦酯增加了附睾PPARγ mRNA的表达。坎地沙坦酯对脂肪因子产生和释放的影响可能归因于PPARγ激活和/或脂肪细胞大小减小。此外,坎地沙坦酯治疗增加了附睾血管紧张素II AT(2)受体mRNA和蛋白的表达,并降低了肾素受体mRNA的表达。这些结果表明,坎地沙坦酯通过促进脂肪组织重排和调节脂肪因子表达及释放来影响脂肪组织中的脂质代谢。这些作用可能是局部血管紧张素II AT(1)受体抑制、血管紧张素II AT(2)受体刺激以及可能的其他不依赖血管紧张素II的机制的结果。我们的结果表明,局部肾素-血管紧张素系统的活性在脂肪组织代谢中起重要作用。促炎细胞因子TNFα的减少和抗炎脂肪因子脂联素的增加表明,坎地沙坦酯可能具有显著的抗炎特性。